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AbStrACt
background Optimizing and ensuring the quality of 
surgical care is essential to improve the management and 
outcome of patients with cervical cancer.
ObjECtivE
To develop a list of quality indicators for surgical treatment 
of cervical cancer that can be used to audit and improve 
clinical practice.
Methods Quality indicators were developed using a 
four- step evaluation process that included a systematic 
literature search to identify potential quality indicators, 
in- person meetings of an ad hoc group of international 
experts, an internal validation process, and external 
review by a large panel of European clinicians and patient 
representatives.
results Fifteen structural, process, and outcome 
indicators were selected. Using a structured format, each 
quality indicator has a description specifying what the 
indicator is measuring. Measurability specifications are 
also detailed to define how the indicator will be measured 
in practice. Each indicator has a target which gives 
practitioners and health administrators a quantitative basis 
for improving care and organizational processes.
Discussion Implementation of institutional quality 
assurance programs can improve quality of care, even in 
high- volume centers. This set of quality indicators from 
the European Society of Gynaecological Cancer may be 
a major instrument to improve the quality of surgical 
treatment of cervical cancer.
iNtrODUCtiON
Cervical cancer has become less common in Europe 
but is still a major public health problem. The esti-
mated number of new cases of cervical cancer in 
Europe in 2018 was 61 000, with 25 800 deaths.1 
Five- year relative survival for European women 
diagnosed with cervical cancer in 2000–2007 was 
62%, ranging from 57% in Eastern Europe to 67% in 
Northern Europe. Survival was particularly low (<55%) 
in Bulgaria, Latvia, and Poland and highest in Norway 
(71%).2 The large geographic variation in rates of 
cervical cancer reflects differences in the availability 
of screening and in the prevalence of human papillo-
mavirus (HPV) infection. The quality of surgical care 
as a component of comprehensive multi- disciplinary 
management has been shown to improve outcomes 
in patients with other types of malignancies.3 4 Imple-
mentation of a quality improvement program helped 
to reduce both morbidity and costs in other tumors 
where surgical interventions are also high risk. Thus, 
it is likely that implementation of a quality manage-
ment program could improve survival of patients with 
cervical cancer.
The aim of this project was to develop a list of 
quality indicators for surgical treatment of cervical 
cancer that can be used to audit and improve clin-
ical practice in an easy and practicable way. These 
quality indicators are intended to give practitioners 
and administrators a quantitative basis to improve 
care and organizational processes. They also facilitate 
the documentation of quality of care, the comparison 
of performance structures, and the establishment of 
organizational priorities as a basis for accreditation 
in European countries. The key characteristics of an 
ideal indicator are clear definition, clinical relevance, 
measurability, and feasibility in clinical practice.
The quality indicators and proposed targets are 
based on the standards of practice determined from 
available scientific evidence and/or expert consensus. 
The indicators are defined according to the tumor 
node metastasis classification, as a recommended 
tool for staging patients with cervical cancer in the 
current version of clinical guidelines jointly developed 
by the European Society of Gynaecological Oncology 
(ESGO), the European Society for Radiotherapy and 
Oncology (ESTRO), and the European Society of 
Pathology (ESP).5–7 Incorporation of the 2018 revised 
FIGO staging for carcinoma of the cervix uteri8 in the 
joint ESGO- ESTRO- ESP guidelines5–7 will be eval-
uated in an upcoming update. The idea behind the 
project is to improve the standard of surgical care by 
providing a set of quality criteria that can be used for 
self- assessment, for an institutional quality assurance 
program, for governmental quality assessment, and 
eventually, to build a network of certified centers for 
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Figure 1 Development process: a four- step evaluation. IDG, international development group; QI, quality indicator.
MEthODS
Quality indicators for the surgical treatment of cervical cancer were 
developed using a four- step evaluation process (Figure  1). This 
development process involved two physical meetings of an ad hoc 
international development group, chaired by Professor David Cibula 
(Gynecologic Oncology Center, First Faculty of Medicine, Charles 
University and General University Hospital, Prague, Czech Republic), 
convened on February 8, 2019 and May 24, 2019.
Nomination of an international Development Group
The ESGO Council and the European network for gynecological 
oncological trial collaborative groups nominated 16 surgeons from 
among the ESGO members, whose expertise had been previously 
checked/confirmed by identifying articles, oral presentations, 
administrative responsibilities, and other works of any type on 
leadership in improving the quality of care for patients with cervical 
cancer. Potential conflicts of interests were also checked before 
the beginning of the development process. Countries across Europe 
were represented. The experts of the development group were 
required to inform the ESGO council promptly if any change in the 
disclosed information occurred during the course of the project. The 
experts are listed in online supplementary Appendix 1.
identification of Potential Quality indicators
All possible quality indicators for cervical cancer surgery 
were identified from the ESGO- ESTRO- ESP guidelines5–7 
and published indicators. A systematic literature search was 
conducted in Medline without any restriction of the search 
period, using the following indexing terms: quality indicators, 
quality assurance, cervical cancer, uterine cervical neoplasms, 
surgery, methodology, consensus statements, and evidence- 
based medicine. References were selected if they described 
indicators developed by other agencies or synthesized research 
evidence describing practice contributing to improved patient 
outcomes (guidelines or consensus statements). Four previous 
initiatives publishing quality indicators for cervical cancer 
surgery were identified.9–12
Evaluation of Potential Quality indicators
Possible quality indicators were formatted as a questionnaire 
and sent to the international development group. Experts were 
asked to evaluate each indicator according to relevance and 
feasibility in clinical practice (evaluation No 1). They were 
also free to propose any additional possible quality indicators 
they deemed relevant. Responses were pooled and organized 
according to consensus for relevance, feasibility, and quality 
of care improvement. The results of this first evaluation was 
sent to experts who convened during the first 1- day meeting 
(February 8, 2019). Acceptance, rejection, or the need for 
further consideration of each indicator was discussed during 
the meeting (evaluation No 2). Candidate quality indica-
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Table 1 Quality indicators related to caseload in the 
center, and training and experience of the surgeon
QI 1 - Number of radical procedures (parametrectomies) in 
cervical cancer performed per center per year
  Type Structural indicator
  Description A radical procedure is defined as one 
that includes parametrectomy (eg, radical 
hysterectomy, radical trachelectomy, 
parametrectomy)
  Specifications Numerator: number of radical procedures as 
defined above performed per center per year
Denominator: not applicable
  Targets Optimal target:≥30
Minimum required target:≥15
QI 2 - Surgery performed or supervised by a certified 
gynecologic oncologist or a trained surgeon dedicated to 
gynecological cancer
  Type Process indicator
  Description Surgery is performed or supervised by a 
certified gynecologic oncologist or by a 
trained surgeon dedicated to gynecological 
cancer (accounting for over 80% of his or 
her practice) or having completed an ESGO- 
accredited fellowship
  Specifications Numerator: number of patients with cervical 
cancer operated by a surgical specialist (as 
defined above)
Denominator: number of patients undergoing 
surgery for cervical cancer
  Target 100%
External Evaluation of the retained Quality indicators: 
international review
The ESGO Council established a large panel of practicing clini-
cians who provide care to patients with cervical cancer or who had 
been treated for cervical cancer in the past. These international 
reviewers are independent of the international development group. 
Another requirement was balanced representation of countries 
across Europe. The retained indicators were formatted as a ques-
tionnaire and sent to the reviewers for quantitative evaluation of 
each indicator according to relevance, feasibility in clinical practice, 
and quality of care improvement (physicians only). Open comments 
were encouraged (qualitative evaluation). Patients were asked to 
qualitatively evaluate each quality indicator (according to their 
experience, preferences, feelings, etc). Evaluations of the indicators 
were returned by 94 independent physicians and by three patients 
with cervical cancer (the list of international reviewers is available 
in online supplementary Appendix 2). Responses were pooled and 
sent to experts who convened during the second 1- day meeting 
(May 24, 2019). The results of the external quantitative and qual-
itative evaluations were examined, and confirmed the choice of 
the retained quality indicators. All comments were reviewed and 
discussed by the international development group members. Of 
note, although the strengths of the process include an international 
development group, an international expert consensus to support 
the quality indicators, an international external review process 
(physicians and patients), a structured format to present the quality 
indicators, and management of potential conflicts of interests, the 
quality indicators result from a consensus of experts, with inherent 
bias in this type of method. They may have to be modified in the 
future, based on publication of new data and upcoming update of 
the ESGO- ESTRO- ESP guidelines.
rESULtS
Each retained quality index is categorized as a structural indicator, 
process indicator, or outcome indicator13 and has a description 
which specifies what the indicator is measuring. The measura-
bility specifications are then detailed. The latter highlight the way 
in which the indicator will be measured in practice to allow audits. 
The time frame for assessment of criteria is the last calendar year 
(unless otherwise indicated). Further to measurement of the indi-
cator, a target is indicated. This specifies the level which each unit/
center should be aiming to achieve. When appropriate, two targets 
were defined: an optimal target, expressing the best possible option 
for patients and a minimal target, expressing the minimal require-
ment when practical feasibility factors are taken into account. 
Whenever available, corresponding published data are described. 
If not, the targets are based on database analysis of international 
development group members or on expert consensus. Quality indi-
cators 1 and 2 are related to caseload in the center, training, and 
experience of the surgeon (Table 1). Quality indicators 3 to 5 are 
related to the overall management, including active participation 
in clinical research, decision- making process within a structured 
multi- disciplinary team, and pre- operative investigation (Table 2). 
Quality indicators 6 to 8 highlight the need to record relevant infor-
mation in order to improve quality (Table 3). Quality indicators 9 to 
12 are related to the quality of surgical procedures (Table 4). Quality 
indicators 13 to 15 are related to the compliance of management 
with the standards of care (Table 5).
Center Case Load, training, and Experience of the Surgeon
Although hospital volume alone does not guarantee surgical quality, 
it is a prerequisite. The effect of hospital volume on outcomes of 
surgery for patients with cancer is related to a surgeon’s skill and 
experience defined notably by surgical volumes, and by hospital 
infrastructure and the supporting team dedicated to surgical care. 
Data support a positive relationship between surgical volume and 
outcomes (eg, survival, increased technical expertise, adherence to 
evidence- based treatment recommendations, appropriate manage-
ment of complications) for different types of cancer,14–37 indicating 
a benefit for centralization of care pathways. In a systematic review 
and meta- analysis by Lee et al38 of the impact of hospital volume of 
laparoscopic radical hysterectomy on treatment outcomes of 4367 
patients with cervical cancer, high volume was a favorable prog-
nostic factor for operative outcomes and peri- operative complica-
tion rates. Hospitals were classified as high volume (≥15 cases/
year) or low volume (<15 cases/year). In this study, in which high- 
volume hospitals included cases with relatively more advanced 
stages, survival outcome was favorable in high- volume hospitals, 
although the difference did not reach statistical significance.
A large nation- wide retrospective observational study in institu-
tions of the Japanese Gynecologic Oncology Group examined 5964 
consecutive women with clinical stage Ib1–IIb cervical cancer 
undergoing radical hysterectomy and pelvic lymphadenectomy.39 
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Table 2 Quality indicators related to the overall management
QI 3 - Center participating in ongoing clinical trials in gynecological cancer
  Type Structural indicator
  Description The center actively accrues patients in ongoing clinical trials (not restricted to surgery) in 
gynecological cancer
  Specifications Numerator: number of ongoing clinical trials in gynecological cancer (not restricted to surgery 
only)
Denominator: not applicable
  Target ≥1
QI 4 - Treatment discussed at a multi- disciplinary team meeting
  Type Process indicator
  Description The decision for any therapeutic intervention (excluding any diagnostic procedure—that is, 
biopsies or conization performed with a diagnostic intent) has been taken by a multi- disciplinary 
team including at least a gynecologic oncologist or a trained surgeon specifically dedicated to 
gynecological cancer as defined above (quality indicator 2), a radiologist, a radiation oncologist, a 
medical or clinical oncologist, and a pathologist
  Specifications Numerator: number of patients with cervical cancer for whom the decision for any therapeutic 
intervention has been made by a multi- disciplinary team
Denominator: all patients presenting with cervical cancer
  Target 100%
QI 5 - Required pre- operative investigation
  Type Process indicator
  Description The required pre- operative investigation is defined according to the ESGO- ESTRO- ESP 
guidelines5–7
  Specifications Numerator: number of patients with cervical cancer for whom surgery is planned who received 
pre- operative investigation according to the ESGO- ESTRO- ESP guidelines5–7
Denominator: all patients with cervical cancer for whom surgery is planned
  Target 100%*
*Need to specify if the required pre- operative investigation, defined according to the ESGO- ESTRO- ESP guidelines,5–7 is not followed
In that study, surgery at high- volume centers, defined as ≥21 
cases a year, was associated with decreased local recurrence risk 
and improved survival on multi- variable analysis, suggesting that 
hospital volume may be a prognostic factor for early- stage cervical 
cancer. The study examined surgical volume for each institution, 
not for each surgeon; did not examine the route of radical hyster-
ectomy; and analyzed only oncologic outcome, not peri- operative 
complications or patient- reported outcomes.
In view of the declining incidence of cervical cancer, notably 
in Western Europe, there is an argument for centralizing surgical 
care. The quality of radical procedures could be improved by such 
centralization. In Europe, organization of gynecologic oncology 
differs among countries, but there is a trend towards centraliza-
tion and sub- specialization. The ESGO, in collaboration with the 
European Board and College of Obstetricians and Gynecologists, 
has developed a sub- specialty training program in gynecologic 
oncology. Increasing evidence shows that physicians with different 
sub- specialty backgrounds affect treatment outcomes of patients 
with malignant disease.40–42 Wu et al43 explored this hypothesis for 
patients with cervical cancer specifically. They found significant 
benefits in surgical outcomes and survival for patients undergoing a 
radical hysterectomy performed by a gynecologic oncologist rather 
than by a non- gynecologic oncologist. In addition, positive surgical 
margins were more frequently detected in patients of the non- 
gynecologic oncologists group, from an oncological perspective. 
This suggests that gynecologic oncologists would be more likely to 
ensure the radicality of radical hysterectomy and therefore better 
disease control. According to the ESGO- ESTRO- ESP guidelines,5–7 
treatment should be undertaken by a dedicated team of specialists 
in the diagnosis and management of gynecologic cancers. Radical 
surgery performed by a gynecologic oncologist is the preferred 
treatment modality in early- stage disease.
Overall Management
Clinical research is crucial to improve the quality of care. Patients 
with ovarian cancer treated in study hospitals had a higher chance 
of receiving standard treatment than those treated in hospitals not 
participating in clinical studies.44 45 Study centers recruited patients 
and had the infractructure required for entering patients into clin-
ical trials. They also might participate more often in quality assur-
ance program. The benefit extended even to patients not enrolled 
in protocols.44
Multi- disciplinary care is internationally recognized as best 
practice in treatment planning and care. In several types of cancer, 
evidence shows that decisions made by a multi- disciplinary team 
are more likely to be in accord with evidence- based guidelines 
than those made by individual clinicians, and the role of the multi- 
disciplinary approach in the quality of care is recognized.46–54 
According to the ESGO- ESTRO- ESP guidelines,5–7 treatment plan-
ning should be made on a multi- disciplinary basis (generally at a 
copyright.
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Table 3 Quality indicators related to recording pertinent information (surgical reports, pathology reports, recording of post- 
operative complications)
QI 6 - Minimum required elements in surgical reports
  Type Process indicator
  Description The required surgical report, based on the ESGO- ESTRO- ESP guidelines,5–7 includes at least the 
elements mentioned above
  Specifications Numerator: number of patients with cervical cancer undergoing surgery who have a complete 
surgical report that contains all required elements as defined above
Denominator: all patients with cervical cancer undergoing surgery
  Target 100%
QI 7 - Minimum required elements in pathology and pathology reports
  Type Process indicator
  Description The minimum required elements in pathology and pathology reports, based on the ESGO- ESTRO- 
ESP guidelines,5–7 include at least the elements mentioned above (Box 1)
  Specifications Numerator: number of patients with cervical cancer undergoing surgery for whom all minimum 
required elements as defined above are reported
Denominator: all patients with cervical cancer undergoing surgery
  Target ≥90%*
QI 8 - Structured prospective reporting of the follow- up and 30- day post- operative morbidity
  Type Outcome indicator
  Description Structured prospective reporting of the follow- up and 30- day post- operative morbidity using a 
validated surgical complications scoring system
  Specifications Numerator: number of patients with cervical cancer who have undergone a surgery and for 
whom a structured prospective reporting of the follow- up and 30- day post- operative morbidity is 
available
Denominator: all patients with cervical cancer undergoing surgery
  Targets Optimal target:≥90%.
Minimum required target: selected cases are discussed at morbidity and mortality conferences
*The tolerance with this target reflects situations where it is not possible to report all components owing to poor quality of the specimen.
tumor board meeting) and based on the comprehensive and precise 
knowledge of prognostic and predictive factors for oncological 
outcome, morbidity, and quality of life. Treatment requires central-
ization and involvement of a broad multi- disciplinary team, including 
at least a gynecologic oncologist or a trained surgeon specifically 
dedicated to the management of gynecological cancers (see quality 
indicator 2), a radiologist, a radiation oncologist, a medical or clin-
ical oncologist, and a pathologist. A structured program for multi- 
disciplinary diagnostic investigation, treatment, and follow- up must 
be present.
An accurate diagnosis guides patient management and informs 
prognosis. According to the ESGO- ESTRO- ESP guidelines,5–7 pelvic 
examination and biopsy, with or without colposcopy, are mandatory 
components for the diagnosis of cervical cancer. Magnetic reso-
nance imaging is the obligatory initial investigation for assessment 
of the extent of a pelvic tumor and to guide treatment options. Endo-
vaginal/transrectal ultrasound is an option if performed by a prop-
erly trained sonographer. In locally advanced cervical cancer (T1b2 
and higher (except T2a1)) or in early- stage disease with suspicious 
lymph nodes on imaging, positron emission tomography- computed 
tomography, or chest/abdomen computed tomography is recom-
mended for assessment of nodal and distant disease. Equivocal 
extra- uterine disease is to be considered for biopsy to confirm or 
rule out metastatic disease and to avoid inappropriate treatment. 
Tru- Cut (core- cut) biopsy is preferred rather than fine- needle 
aspiration biopsy because it allows histological assessment of the 
tissue.
recording Pertinent information for improving Quality
Evidence shows that standardized operative reports result in 
more complete and reliably interpretable operative data than non- 
standardized operative reports.55 Compliance with the standardized 
operative report improves over time. Synoptic operative reports 
have been used in other surgical disciplines such as orthopedics 
and colorectal surgery, although they have not been evaluated 
extensively.56 57 ESGO has approved a template for ovarian cancer 
operative reports.58
In the absence of an international validated standardized 
surgical report in cervical cancer, some required elements must 
be reported. As mentioned in the ESGO- ESTRO- ESP guidelines,5–7 
the surgical report must be structured and should include at least 
the following elements: surgical approach; type of lymph nodes 
staging; technique of sentinel lymph node (SLN) detection; local-
ization of detected sentinel lymph node; regions of pelvic lymph 
node dissection; detailed description of type of parametrial resec-
tion (Querleu- Morrow classification59; type of adnexal procedure; 
localization of preserved adnexa/ovaries; basic surgical data (dura-
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Table 4 Quality indicators related to the quality of surgical procedures
QI 9 - Urological fistula rate within 30- post- operative days after a radical parametrectomy
  Type Outcome indicator
  Description Any bladder or ureteral fistula diagnosed after a procedure including radical parametrectomy. 
The fistula rate should be calculated on the basis of data of the preceding 3 years. Radical 
parametrectomies include radical hysterectomies, radical trachelectomies, and parametrectomies
  Specifications Numerator: number of patients treated in the preceding 3 years who develop ureteral or bladder 
fistulas within 30- post- operative days
Denominator: all patients with cervical cancer undergoing a procedure including radical 
parametrectomy in the preceding 3 years
  Target ≤3%
QI 10 - Proportion of patients after primary surgical treatment who have clear vaginal (invasive disease) and parametrial 
margins
  Type Outcome indicator
  Description Clear surgical margins apply for both the vaginal margins and parametrial margins. Using an 
adequate clinical staging with modern imaging and careful pre- operative vaginal assessment, as 
defined in the ESGO- ESTRO- ESP guidelines,5–7 positive surgical margins after a radical hysterectomy 
or trachelectomy should be avoided
  Specifications Numerator: number of patients after primary surgical treatment who have clear surgical margins for 
invasive disease in the preceding 3 years
Denominator: all patients who have undergone primary surgical treatment in the preceding 3 years
  Target ≥97%
QI 11 - Proportion of patients with a stage T1b disease T- upstaged after surgery
  Type Outcome indicator
  Description T- upstaging refers to detection of any involvement of parametria or vagina found on pathology 
which was unknown before surgery, or a stage shift from T1b1 to T1b2 or higher, from pre- operative 
assessment to post- operative pathology. Detection of positive LNs is not included
  Specifications Numerator: number of patients with stage T1b disease T- upstaged after surgery, as defined above
Denominator: all patients with a stage T1b who have undergone a surgery
  Target <10%
QI 12 - Recurrence rate at 2 years in patients with a stage pT1b1 with negative lymph nodes (LNs) after primary surgical 
treatment
  Type Outcome indicator
  Description This quality indicator applies to the common tumor types (squamous cell and usual types of 
adenocarcinoma) and both local or distant recurrences, irrespective of adjuvant treatment strategy
  Specifications Numerator: lymph nodes- negative pT1b1 patients whose disease recurs within 2 years after primary 
surgical treatment, irrespective of adjuvant treatment strategy, with a minimum of 2 years' follow- up.
Denominator: All lymph nodes- negative pT1b1 patients after primary surgical treatment, irrespective 
of adjuvant treatment strategy, with a minimum of 2 years' follow- up.
  Target <10%
The pathology report is a key component in the management of 
patients with cancer and its accuracy depends on several factors. 
Pre- analytical steps must be carried out in an optimal way to allow 
for adequate pathological evaluation. The inclusion of informa-
tive clinical and surgical data on the pathology request form, and 
accurate sampling and processing of the specimens, are the basis 
for a correct histological diagnosis and the provision of informa-
tion on tumor staging and prognosis. The pathology report should 
comprehensively include all the features that enable a patient with 
cervical carcinoma to be placed into a risk group, which ensures 
the appropriate management. It should include all the parameters 
affecting tumor staging and patient management. The histolog-
ical sub- type is important as some uncommon tumor types are 
associated with aggressive behavior (eg, high- grade neuroendo-
crine carcinoma and gastric- type adenocarcinoma) or favorable 
behavior (eg, adenoid- basal carcinoma) and may be considered for 
different treatment. Histological tumor grade is generally reported 
in squamous cell carcinomas and adenocarcinomas but, in general, 
this does not affect the treatment and the prognosis, especially as 
there is no validated grading system for these cancers. Accurate 
tumor measurement, which often requires correlation of the gross 
and microscopic features, is important for sub- staging of tumors. 
The presence or absence of lymphovascular space involvement, the 
lymph nodes status (number of nodes retrieved, number involved, 
presence of extra- capsular extension, size of metastasis), involve-
ment of extra- cervical tissues, and the margin status, including the 
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Table 5 Quality indicators related to the compliance of management with the standards of care
QI 13 - Proportion of patients with a stage T1 disease treated by primary surgery who have undergone lymph node (LN) 
staging according to the ESGO- ESTRO- ESP guidelines
  Type Outcome indicator
  Description Lymph nodes staging is defined according to the ESGO- ESTRO- ESP guidelines5–7
  Specifications Numerator: number of patients with a stage T1 disease who have undergone Lymph nodes staging 
according to the ESGO- ESTRO- ESP guidelines5–7
Denominator: all patients with a stage T1 disease who were treated by primary surgery
  Target ≥98%
QI 14 - Counseling about a possibility of FST
  Type Structural indicator
  Description Counseling of patients with stage T1b1 ≤2 cm disease, potential candidates for fertility- sparing 
treatment, is described in the ESGO- ESTRO- ESP guidelines.5–7 All eligible patients should be 
appropriately counseled about a possibility of FST. FST should be undertaken exclusively in centers 
with comprehensive expertise in this management
  Specifications Numerator: number of patients with stage T1b1 ≤2 cm disease, potential candidates for FST, 
counseled according to the ESGO- ESTRO- ESP guidelines5–7
Denominator: all patients with stage T1b1 ≤2 cm disease, potential candidates for FST
  Target 100%
QI 15 - Proportion of patients receiving adjuvant chemoradiotherapy after a primary surgical treatment for a stage pT1b1 pN0 
disease
  Type Structural indicator
  Description Management of patients after a surgical treatment for a stage pT1b1 pN0 disease is defined 
according to the ESGO- ESTRO- ESP guidelines5–7
  Specifications Numerator: number of patients receiving adjuvant chemoradiotherapy after primary surgical 
treatment for stage pT1b1 pN0 disease, according to the ESGO- ESTRO- ESP guidelines5–7
Denominator: all patients with primary surgical treatment for stage pT1b1 pN0 disease
  Target <15%
distance of tumor and pre- invasive disease to various margins, are 
also critical for patient management.T
The international development group considers that widespread 
use of the requirements for the pathology report for cervical cancer, 
listed in Box 1 and defined as part of the ESGO- ESTRO- ESP guide-
lines,5–7 will improve patient management and is a prerequisite for 
research and for international benchmarking in healthcare.
The lack of a consensus within the surgical community on how 
to report surgical complications has hindered progress in surgical 
research. The therapy used to manage a specific complication 
remains the cornerstone for ranking a complication. Conclusive 
assessments of surgical procedures remained limited on how to 
define and stratify complications. In 1992, Clavien et al60 proposed 
a standardized system, modified in 2004 by Dindo et al,61 based 
on the intervention needs and health of the patient. This Clavien- 
Dindo classification, based on the therapeutic consequences of 
complications, consists of five severity grades and focuses on the 
medical perspectives, with a major emphasis on the risk and inva-
siveness of the therapy used to correct a complication. A 5- year 
evaluation demonstrated its validation, reproducibility, and appli-
cability worldwide, irrespective of the cultural background and in 
many fields of surgery.62 Other classifications were proposed in 
the 1990s63–65 but are used less frequently. The Common Termi-
nology Criteria for Adverse Events, are oriented more towards 
medical outcomes than the Clavien- Dindo classification. Identi-
fying 129 studies using the Clavien- Dindo classification as the 
basis for classifying post- operative complications, Strasberg et al66 
determined how well this classification and its modifications has 
functioned as a severity grading system. These authors proposed 
a modified severity grading system, the 'Accordion classification', 
geared towards making the classification more useful in studies of 
different size and complexity.
In 2013, Slankamenac et al67 developed a comprehensive compli-
cation index that takes into account all complications after a proce-
dure and their respective severity. The development of this index 
was based on the adapted Clavien- Dindo classification system. The 
complications were weighted with different severities by adopting 
an 'operation risk index' approach. The value of the comprehen-
sive complication index has been explored in three randomized 
controlled trials.68 These trials showed a greater ability to detect 
differences between treatment effects than classic endpoints such 
as 'any complication' or 'major complication' defined according to 
the Clavien- Dindo classification. The index has been used in large 
multi- centric studies,69–77 notably as a benchmark endpoint for 
major surgery.70 Exploring the potential added value of the compre-
hensive comprehensive index to standard assessment of post- 
operative morbidity, and to clarify potential controversies for its 
application, Clavien et al78 reported that it yielded substantial addi-
tional value to the Clavien- Dindo classification in patients with more 
than one complication. In particular, its value increases after major 
surgery and with inclusion of the observation time after surgery. 
This, however, does not justify the replacement of one system by 
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box 1 Minimum requirements for pathology report for 
cervical cancer
1. Description of the specimen(s) submitted for histological evaluation
2. Macroscopic description of specimen(s) (biopsy, loop/cone, tra-
chelectomy, hysterectomy), including specimen dimensions (three 
dimensions), number of tissue pieces for loop/cones, and maxi-
mum and minimum length of vaginal cuff and the parametria in 
two dimensions
3. Macroscopic tumor site(s), if the tumor is visible grossly, in tra-
chelectomy and hysterectomy specimens
4. Tumor dimensions, including two measurements of horizontal ex-
tent and depth of invasion or thickness (tumor dimension should 
be based on a correlation of the gross and histological features). 
When multi- focal separate tumors are present, each should be de-
scribed and measured separately, and the largest used for tumor 
staging. Specimens from prior conization and subsequent coni-
zation, trachelectomy, or hysterectomy should be correlated for 
estimation of the tumor size. This is important because different 
specimens might have been reported at different institutions. It 
should also be recognized that simply adding up the maximum 
size of tumors in separate specimens may significantly over- 
estimate the maximum tumor dimension
5. Histological tumor type and tumor grade
6. The presence or absence of lymphovascular space involvement
7. Co- existing pathology (squamous intra- epithelial lesion/cervi-
cal intra- epithelial neoplasia, adenocarcinoma in situ, stratified 
mucin- producing intra- epithelial lesion)
8. Minimum distance of uninvolved cervical stroma
9. Margin status (invasive and pre- invasive disease, specify the 
margin(s))
10. Lymph node (LN) status, including sentinel lymph node (SLN) 
status, the total number of nodes found, the number and loca-
tion of positive LNs, and the presence of extra- nodal extension. 
Micrometastasis (>0.2 mm and up to 2 mm) are reported as pN1 
(mi). Isolated tumor cells no greater than 0.2 mm in regional nodes 
should be reported as pN0 (i+). The number of positive LNs for 
each anatomical group should be reported separately
11. Pathologically confirmed distant metastases
12. Provisional pathological staging (tumor node metastasis, eighth 
edition110; a pathological FIGO stage8 may also be provided if dic-
tated by local protocols
13. The results of any frozen section specimen evaluation
the other as the Clavien- Dindo classification discloses the highest 
grade of complications and the type of complications.
Using the Clavien- Dindo classification as a guide, the Depart-
ment of Surgery at the Memorial Sloan Kettering Cancer Center 
developed a surgical secondary events database based on grade 
of event and required intervention to begin prospectively recording 
and analyzing all surgical secondary events. In 2008, a blinded 
external audit of 1498 operations, randomly selected to examine 
the quality and reliability of the data, was conducted and demon-
strated the accuracy of data collection.79 A limitation of this data-
base is that it does not capture all grade I and II events.
The international development group considers that the wide-
spread use of a simple, objective, and reproducible approach to 
comprehensive surgical outcome assessment will improve patient 
management. It should be easily applicable by surgeons who are 
less experienced.
Quality of Surgical Procedures
The extensive dissection of the ureters and bladder required during 
radical procedures for cervical cancer leads to a risk of intra- 
operative injuries of the ureter and the bladder and the develop-
ment of post- operative fistulas.80 The total incidence of urologic 
fistulas after radical surgery for cervical cancer surgery does not 
exceed 5.1% but can vary, depending notably on the proportion of 
patients with advanced disease included in the series.81–88 Most 
fistulas are secondary to extensive dissection, leading to ischemic 
damage rather than unrecognized intra- operative full- thickness 
visceral injury.89 Urogenital fistulas significantly increase post- 
operative morbidity.90
The quality of radical surgery has a great impact on local 
control, underlining the importance of optimal surgical care. The 
achievement of clear margins is a major prognostic factor. No 
ideal tumor- free margin distance has been defined which should 
be achieved after radical trachelectomy or hysterectomy. Positive 
surgical margins after radical hysterectomy or trachelectomy in 
patients with a stage T1 disease should be avoided. Similarly, a high 
proportion of T- upstaged patients after surgery reflects poor quality 
of pre- operative imaging and surgery planning. Pre- treatment 
staging is crucial for decisions on choice of treatment and tailoring 
of surgical radicality. Both the uterine procedure (performance of 
parametrectomy) and lymph nodes staging should be tailored to the 
main prognostic factors disclosed (or assessed or evaluated) pre- 
operatively, including tumor size and the involvement of parametria. 
Adequate clinical staging with modern imaging and careful pre- 
operative vaginal assessment should be performed, and radicality 
of surgery should be tailored as defined in the ESGO- ESTRO- ESP 
guidelines.5–7
According to the available prospective and retrospective 
studies,91–106 less than 15% of patients with stage pT1b1 disease 
and negative lymph nodes develop recurrent disease within 
2 years of primary surgical treatment, irrespective of the neo- 
adjuvant or adjuvant treatment strategy. More recently, Ramirez 
et al107 reported, as part of the Laparoscopic Approach to Cervical 
Cancer trial, disease- free survival and loco- regional recurrence- 
free survival rates at 3 years of higher than 90% for patients with 
a stage IB1 disease, irrespective of the lymph nodes status and 
surgical approach. Thus, a recurrence- free survival rate at 2 years 
of less than 90% in patients with a stage IB1 disease with nega-
tive lymph nodess after primary surgery treated in gynecologic 
oncology centers should be considered as a failure of management.
Compliance of Management with the Standards of Care
According to the ESGO- ESTRO- ESP guidelines,5–7 lymph nodes 
staging is not indicated in T1a1 patients who have no lymphovas-
cular space involvement but can be considered in those who do have 
such involvement. For T1a2 patients with no lymphovascular space 
involvement, lymph nodes staging can be considered but should 
be performed in those with positive involvement. Sentinel lymph 
node biopsy alone (without additional pelvic lymph node dissection) 
appears to be an acceptable method of lymph nodes staging in 
T1a disease (except in T1a1 patients with no lymphovascular space 
involvement). For management of a T1b1 disease, the standard 
lymph nodes staging procedure is systematic pelvic lymphad-
enectomy. Sentinel lymph node biopsy before pelvic lymphad-
enectomy is strongly recommended because it increases staging 
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accuracy—namely, the identification of micrometastases (<2 mm 
in the largest diameter) and small micrometastases (slightly larger 
than 2 mm). Combination of blue dye with radio- colloid or use of 
indocyanine green alone is the recommended technique. Lymph 
nodes assessment should be performed as the first step of surgical 
management as it allows intra- operative Sentinel lymph node/lymph 
nodes assessment and the avoidance of radical parametrectomy in 
patients with intra- operativelly detected lymph nodes involvement. 
Intra- operative assessment of lymph nodes status (frozen section) 
is recommended. All sentinel nodes from both sides of the pelvis 
and/or any suspicious LNs should be sent for frozen section. If a 
sentinel node is not detected, intra- operative assessment of the 
pelvic LNs should be considered. If intra- operative lymph nodes 
assessment is negative or not carried out, systematic pelvic lymph 
node dissection should be performed. Sentinel lymph node biopsy 
alone is not recommended in stage T1b outside of clinical trials. 
Systematic lymph nodes dissection should include the removal of 
lymphatic tissue from regions with the most frequent occurrence of 
positive LNs (Sentinel lymph node), including the obturator fossa, 
the external iliac regions, the common iliac regions bilaterally, and 
the pre- sacral region.108 If lymph nodes involvement is detected 
intra- operatively, including macrometastases or micrometastases, 
further pelvic lymph node dissection and radical hysterectomy 
should be avoided. Para- aortic lymph node dissection, at least up 
to the inferior mesenteric artery, may be considered for staging 
purposes. Negative pelvic lymph nodes status is the pre- condition 
for any fertility- sparing treatment. Therefore, pelvic lymph nodes 
(Sentinel lymph node) staging should always be the first step in 
such a procedure. Identification of sentinel lymph nodes and its 
ultra- staging is highly recommended because it increases staging 
accuracy. The involvement of suspicious LNs should be confirmed 
by histology.
For patients who consider fertility- sparing treatment, consul-
tation at a fertility center is recommended. The treatment should 
exclusively be undertaken in gynecologic- oncological centers with 
comprehensive expertise in this type of oncologic therapy. Prog-
nostic factors, clinical staging, and pre- operative investigation do 
not differ from those who do not consider this treatment. Every 
woman with a desire to spare fertility and histologically proven 
squamous cell carcinoma or usual- type (HPV- related) adenocarci-
noma ≤2 cm of the largest diameter should be counseled about the 
possibility of fertility- sparing treatment. This consultation should 
encompass the possibility of abandoning fertility- sparing treat-
ment if there are positive margins or lymph nodes involvement and 
oncologic and obstetric risks related to this type of management. 
Fertility- sparing treatment should not be recommended for rare 
histological sub- types of cervical cancer, including neuroendo-
crine carcinomas and non- HPV- related adenocarcinomas (except 
for adenoid basal carcinoma), which tend to exhibit aggressive 
behavior. Expert sonography and/or pelvic MRI are recommended 
imaging tests to measure remaining (after cone biopsy) cervical 
length and non- involved cervical length. However, no imaging 
system can predict exactly the extent of necessary local resection 
in order to reach sound margins with adequate safety distance. 
Fertility- sparing treatment in patients with tumors >2 cm cannot 
be recommended and is considered as an experimental approach.
According to the ESGO- ESTRO- ESP guidelines,5–7 treatment 
for patients with stage T1b1 cervical cancer should aim to avoid 
combining radical surgery and radiotherapy because of the high 
morbidity after combined treatment. Adjuvant radiotherapy should 
be considered in the presence of a combination of risk factors at 
final pathology, such as tumor size, lymphovascular space involve-
ment, and depth of stromal invasion. If a combination of risk factors 
is known at diagnosis which would require an adjuvant treatment, 
definitive chemoradiotherapy and brachytherapy can be considered 
without previous radical pelvic surgery. When in these situations an 
adequate type of radical hysterectomy has been performed, obser-
vation is an alternative option, especially in teams experienced in 
this approach.109
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